肝脂肪变是疾病还是皇帝的新衣?
文章重新审视脂肪性肝病定义,区分单纯肝脂肪积累与真正肝病。MASLD全球患病率25-30%,但仅少数进展为晚期肝病;MASH约5%。肝纤维化分期、代谢障碍严重度等决定不良结局风险。单纯脂肪变以心血管代谢管理为主,MASH或MASLD伴纤维化需肝脏靶向干预。
要点
- MASLD全球患病率25-30%,不代表需诊治的肝病患病率。
- MASH全球患病率约5%,肝纤维化分期决定不良肝脏结局风险。
- 单纯脂肪变以心血管代谢管理为主,MASH或纤维化需肝脏靶向干预。
核心结论
- 单纯肝脂肪变是肝病或心血管代谢疾病的风险标志而非独立疾病,MASH和纤维化才是肝相关风险的真正驱动因素。
主要发现
- MASLD全球患病率25-30%,但仅少数进展为晚期肝病。
- MASH全球患病率约5%。
- MASLD/MASH不良肝脏结局风险主要由肝纤维化分期决定,如弹性成像肝硬度>10 kPa。
- 代谢障碍严重度(如2型糖尿病)及其他风险因素(酒精、遗传、年龄和性别)也影响风险。
关键数值与推荐
- 肝纤维化分期(如弹性成像肝硬度>10 kPa)是风险分层关键指标。
- 代谢障碍严重度(如2型糖尿病)及其他风险因素(酒精、遗传、年龄和性别)需纳入评估。
临床怎么用
- 单纯脂肪变以心血管代谢管理为主。
- MASH或MASLD伴纤维化需肝脏靶向干预。
- 区分单纯脂肪变与MASH/纤维化有助于精准风险沟通、靶向监测和治疗,避免不必要的恐慌和资源浪费。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The redefinition of steatotic liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH), has sharpened the distinction between benign hepatic fat accumulation and true liver pathology. MASLD has a global prevalence of 25-30%, but this should not be regarded as the prevalence of individuals with liver disease requiring diagnosis and treatment, as only a minority will progress to advanced disease with liver-related morbidity or mortality. Steatosis alone is often a phenotype or risk marker for liver disease or cardiometabolic disease - not a disease per se in the conventional sense. Clinically relevant liver disease arises when steatosis progresses to steatohepatitis and fibrosis -conditions identifiable by emerging non-invasive tests or histology. MASH has a substantial global prevalence of around 5%. The risk of adverse liver outcomes in MASLD/MASH is primarily determined by the stage of liver fibrosis (e.g. liver stiffness >10 kPa by elastography), severity of metabolic dysfunction (e.g. type 2 diabetes) and other risk factors (e.g. alcohol, genetics, age and sex). From a therapeutic perspective, this distinction underscores that isolated steatosis warrants primarily cardiometabolic management, whereas both established MASH and MASLD with fibrosis require liver-targeted interventions. Recognising the difference between steatosis (not a standalone liver disease) and MASH/fibrosis (true driver of liver-related risk) enables more precise risk communication, guides targeted surveillance and treatment, and helps to avoid unnecessary alarm and inefficient use of resources in already strained healthcare systems. This paradigm shift supports credible, evidence-based public health strategies focused on metabolic health and fibrosis prevention.
引用
- Krag A, Tacke F, Israelsen M, et al. Is liver steatosis a disease or the emperor's new clothes? J Hepatol. 2026. PMID: 41554319. doi:10.1016/j.jhep.2025.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。